Experimental Treatment for Alpha-1 Antitrypsin Deficiency Earns Fast Track Designation
source: unsplash.com

Experimental Treatment for Alpha-1 Antitrypsin Deficiency Earns Fast Track Designation

According to a story from globenewswire.com, the biopharmaceutical company Mereo BioPharma Group plc has recently announced that the company's investigational therapeutic alvelestat has earned Fast Track designation from the US…

Continue Reading Experimental Treatment for Alpha-1 Antitrypsin Deficiency Earns Fast Track Designation